e-Cigarettes Versus NRT Gum for Smoking Cessation
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01925781 |
Recruitment Status :
Terminated
(IND required)
First Posted : August 20, 2013
Results First Posted : January 14, 2016
Last Update Posted : January 14, 2016
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Nicotine Addiction Smoking Cessation | Drug: Nicotine polacrilex Other: STAM 1100mAh CE4 eGo Clearomizer | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 10 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | e-Cigarettes Versus Nicotine Replacement Therapy for Smoking Cessation |
Study Start Date : | August 2013 |
Actual Primary Completion Date : | November 2013 |
Actual Study Completion Date : | November 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: e-Cigarette
STAM 1100mAh CE4 eGo Clearomizer e-Cigarette
|
Other: STAM 1100mAh CE4 eGo Clearomizer
Other Names:
|
Active Comparator: Nicotine polacrilex
Nicotine Replacement gum
|
Drug: Nicotine polacrilex
2 mg and 4 mg gum will be used according to the FDA approved product labelling
Other Name: Nicotine Gum |
- Sustained Abstinence [ Time Frame: 12 weeks ]No smoking at 12 weeks after the predetermined quit date with a 5 day grace period. Self-report will be biochemically confirmed with expired carbon monoxide (CO) and salivary cotinine.
- Point Prevalence Abstinence [ Time Frame: 12 weeks ]No smoking in the previous 7 days. Self report will be biochemically confirmed with expired CO and salivary cotinine.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 19 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Smokes at least five cigarettes per day
- No current or previous regular use of e-cigarettes
- Ready to quit smoking
Exclusion Criteria:
- Use of smokeless or pipe tobacco
- Smoke more than 40 cigarettes per day
- Pregnant or breastfeeding
- Unable to chew gum due to dental or jaw problems
- Myocardial infarction (heart attack) within the previous 12 months
- Hypersensitivity to propylene glycol or nicotine gum

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01925781
United States, Nebraska | |
Creighton University | |
Omaha, Nebraska, United States, 68178 |
Principal Investigator: | Amy J Arouni, MD | Creighton University |
Responsible Party: | Creighton University |
ClinicalTrials.gov Identifier: | NCT01925781 |
Other Study ID Numbers: |
13-16684 |
First Posted: | August 20, 2013 Key Record Dates |
Results First Posted: | January 14, 2016 |
Last Update Posted: | January 14, 2016 |
Last Verified: | December 2015 |
Smoking Cessation Nicotine Addiction e-Cigarette |
electronic nicotine delivery device electronic cigarette nicotine replacement therapy |
Behavior, Addictive Compulsive Behavior Impulsive Behavior Nicotine Ganglionic Stimulants Autonomic Agents Peripheral Nervous System Agents |
Physiological Effects of Drugs Nicotinic Agonists Cholinergic Agonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |